Treace Q1 revenue $52.6M (+3% YoY); net loss improves to $(15.9)M; reaffirms FY2025 guidance

TREACE MEDICAL CONCEPTS, INC.

2025-Q1 EPS reported -$0.25 revenue$52,570,000

Revenue $52.6M, up 3% from $51.1M; adjusted for one less selling day, growth 4.5%.
Net loss $(15.9)M ($(0.25)/share) vs $(18.7)M ($(0.30)/share) in Q1 2024, improved 15%.
Adjusted EBITDA $(3.8)M, a 53% improvement from $(8.3)M in prior-year quarter.
Reaffirms FY2025 revenue guidance $224-230M (7-10% growth) and breakeven adjusted EBITDA.
Launched three new bunion systems (Nanoplasty, Percuplasty 3D MIS, SpeedMTP MTP Fusion).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.